CN102100742A - Water-solubility extract of root of red-rooted salvia, preparation method thereof and application thereof - Google Patents
Water-solubility extract of root of red-rooted salvia, preparation method thereof and application thereof Download PDFInfo
- Publication number
- CN102100742A CN102100742A CN2011100311717A CN201110031171A CN102100742A CN 102100742 A CN102100742 A CN 102100742A CN 2011100311717 A CN2011100311717 A CN 2011100311717A CN 201110031171 A CN201110031171 A CN 201110031171A CN 102100742 A CN102100742 A CN 102100742A
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- salvianolic acid
- solution
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a water-solubility extract obtained by separating root of red-rooted salvia serving as a medicinal raw material, a preparation method thereof and application thereof. The water-solubility extract comprises three salvianolic acid ingredients of salvianolic acid B, danshensu and prolithospermic acid, and the total weight ratio of the salvianolic acid ingredients is between 10 and 90 percent. The invention also provides application of the water-solubility extract of root of red-rooted salvia in the preparation of angiotensin-converting enzyme inhibitor medicaments and medicaments for treating hypertension, hypertension with cardiac failure and hypertension with diabetic nephropathy.
Description
The present invention is for dividing an application, and the original bill application number is 03117546.5, and the original bill applying date is on March 27th, 2003, and the original bill name is called: water solubility extract of Radix Salviae Miltiorrhizae and its production and use.
Technical field
What the present invention relates to is extract of a kind of medicinal raw material and its production and use.Specifically, it is the soluble salvianolic acid extract that obtains by the medicinal raw material Radix Salviae Miltiorrhizae, the extraction preparation method of this extract, and, can be used as the medicine of diseases such as treatment hypertension, heart failure, diabetic nephropathy with the angiotensin converting enzyme inhibitor medicine of this extract as effective medicinal ingredient.
Background technology
Radix Salviae Miltiorrhizae is the dry rhizome of labiate Radix Salviae Miltiorrhizae, is clinical conventional Chinese medicine.The chemical constituent of Radix Salviae Miltiorrhizae mainly is made up of liposoluble constituent and water soluble ingredient two parts, and wherein liposoluble constituent is representative with the TANSHINONES, and pharmacology clinical research confirmation specific examples of such components has good physiologically active.According to " Chinese medicine modern study and application " (second volume) (Zheng Huzhan chief editor; the Xueyuan Press publishes; p1099-1110) report; since the 1980s; many scholars have carried out systematic study to the water soluble ingredient of Radix Salviae Miltiorrhizae; separate and obtain salviol acid A, B, C, D, salviol, multiple phenolic acids chemical constituents such as saivianic acid A, second, third, protocatechuic acid, danshensu, prolithospermic acid." Chinese herbal medicine modern study " (second volume) (write by institute of materia medica, the traditional Chinese medical science Academy of Medical Sciences; combined publication society of China Concord Medical Science University of Beijing Medical University; p492-522) also report; big amount pharmacological research shows; the salvianolic acid compounds has stronger anti peroxidation of lipid, antithrombotic, improves effects such as blood circulation; the activity of salviol acid A and B is the strongest, and to hypoxic-ischemic, the heart and brain cell injury that ischemia-reperfusion causes has obvious protective effect.Publication number is that the Chinese patent literature of CN 1378837A once disclosed danshinolic acid compounds in preparation antithrombotic, antiplatelet aggregation, the application in the medicine that anti-neuronal apoptosis and anti-AIDS infect.Publication number is that the Chinese patent literature of CN 1242364A also discloses the application that contains salvianolic acid extract for treating peptic ulcer.But have not yet to see the research report of relevant salvianolic acid extract in influence aspect the Angiotensin-Converting activity.
Have now and studies show that renin angiotensin extensively is present in the human body, wherein about 15% is present in the blood circulation, and 85% is present in as in the histoorgans such as blood vessel wall, heart, central nervous system, kidney.When the hypertension state, Angiotensin II too much in the blood circulation directly causes vasoconstriction, hypertension, and too much Angiotensin II then can produce the secular damage of histoorgan in the tissue.Angiotensin converting enzyme inhibitor is meant to be a class newtype drug of action target spot at Angiotensin-Converting directly.It stops angiotensin I to generate to Angiotensin II by suppressing Angiotensin-Converting, the degraded of the Kallidin I that slows down, and rising Kallidin I level promotes nitric oxide and prostaglandin to generate, and produces the vasodilator effect.Angiotensin converting enzyme inhibitor can also coronary artery dilator, improve cardiac function when reducing the peripheral blood vessel drag overall, bringing high blood pressure down; Can improve renal blood flow and glomerular filtration rate.The application of angiotensin converting enzyme inhibitor has no adverse effects to glucose metabolism, but and cholesterol reducing and triglyceride, can increase insulin sensitivity, uric acid metabolism is also had no adverse effects, also can sharp sodium, diuresis and do not have the low magnesium disease of low potassium.In addition, angiotensin converting enzyme inhibitor also has good Cardioprotective function, and heart failure that hypertension is caused etc. also has special curative effect.Angiotensin converting enzyme inhibitor not only suppresses the Angiotensin-Converting in the blood circulation; and the Angiotensin-Converting in can also suppressing to organize; thereby the excessive generation of Angiotensin II in the minimizing body, thereby performance controlling blood pressure, the effect of protection target organ.These characteristics in view of the angiotensin converting enzyme inhibitor mechanism of action; angiotensin converting enzyme inhibitor is at present as the novel antihypertensive drugs of the hypertensive class of clinical treatment; not only have the curative effect characteristics that hypotensive effect is strong, side effect is little; especially target organs such as heart, blood vessel and kidney had good protective action; be applicable to the treatment of the hypertension of various degree, now classified as a line antihypertensive drug by World Health Organization (WHO) and China's " hypertension therapeutic guide ".In addition, all right while of angiotensin converting enzyme inhibitor is as the critical treatment medicine of clinical treatment heart failure, renal failure and diabetic nephropathy.
As everyone knows, hypertension, heart failure, diabetic nephropathy are commonly encountered diseases and the frequently-occurring diseases at present clinical, have been several principal diseases of present harm humans health.Therefore, screening study and discovery have Angiotensin-Converting and suppress active new drug from the natural drug raw material, can have good clinical value and market prospect.
Summary of the invention
At above-mentioned situation, the present invention at first will provide a kind of soluble salvianolic acid extract that obtains that extracted by the medicinal raw material Radix Salviae Miltiorrhizae.Further, the present invention will provide a kind of extraction preparation method that obtains said this extract.On this basis, the present invention also will provide with the medicine of said this soluble salvianolic acid extract as the angiotensin converting enzyme inhibitor class of effective medicinal ingredient, can be used as the medicine of aspect diseases such as treatment hypertension, heart failure, diabetic nephropathy.
The invention provides by the medicinal raw material Radix Salviae Miltiorrhizae and separate the water solubility extract that obtains, be to include salvianolic acid B, danshensu, three kinds of salvianolic acid of prolithospermic acid at interior salvianolic acid composition by what extraction in the medicinal raw material Radix Salviae Miltiorrhizae obtained, the gross weight ratio of wherein said salvianolic acid composition is 10-90%, and the gross weight ratio that preferably makes said Radix Salviae Miltiorrhizae total phenolic acids is 30-85%.
It is raw material that the present invention also provides with the medicinal raw material Radix Salviae Miltiorrhizae, can adopt following basic skills to separate to produce and obtain above-mentioned said water solubility extract.
With the medicinal raw material Radix Salviae Miltiorrhizae is that raw material separates the method for producing water solubility extract, comprising:
A, the salvia miltiorrhiza raw material of pulverizing fully flooded extraction with aquiferous ethanol after, to dipping extract the solution that obtains filter and separate the ethanol of removing wherein after obtain remaining water extraction solution, concentrate, the dilution of reuse deionized water, centrifugal, standby;
B, the clear liquid reuse macroporous resin that obtains after a step process is adsorbed, then successively respectively water and aquiferous ethanol wash adsorbent resin respectively, merge eluent, remove the ethanol in the solution and concentrate, obtain extractum shape extract, dry dry powder.
Wherein flood extracting solution with the alcoholic solution of 10-40% for well.The amount of used alcoholic solution is medical material Radix Salviae Miltiorrhizae weight 5-20 times during dipping, and dipping extracts 1-2 time, is at least 24 hours mode at every turn.Said this aquiferous ethanol that eluent uses generally can use volume content to be 60-80%, preferably uses the alcoholic solution of volume content as 70-75%.
In above-mentioned extracting method,, all can adopt conventional distilling under reduced pressure mode to carry out, and obtain remaining water extract solution part removing alcoholic acid operation the alcohol extraction solution from said respectively containing.
Based on the above method, for the extract of resulting this extractum shape, can also again after the vacuum or lyophilization processing of routine, further obtain extract into powdered.
Extract the extractum shape prepare or the product of powdered with said method, be the brownish red water solubility extract that contains said salvianolic acid composition, mildly bitter flavor.With danshensu product in contrast, adopting phenolic compound and the potassium ferricyanide-ferric chloride is chromogenic reaction, and mensuration wherein contains the 10-90% that said Radix Salviae Miltiorrhizae total phenolic acids generally can be gross weight.Wherein this Radix Salviae Miltiorrhizae total phenolic acids extract determines that through separation of silicagel column normal-phase chromatography and structure wherein contain danshensu (I), salvianolic acid B (II), three kinds of liposoluble ingredients of prolithospermic acid (III), chemical structural formula is as follows:
With the above-mentioned said water solubility extract that contains the salvianolic acid composition that is obtained by the separation of medicinal raw material Radix Salviae Miltiorrhizae is effective medicinal ingredient, after pharmaceutically acceptable auxiliary interpolation composition mixes, by corresponding conventional medicine formulation method, can be prepared into the medicine of corresponding angiotensin converting enzyme inhibitor class.For example, after in oral formulations, can receivedly mixing as auxiliary interpolation composition commonly used such as disintegrating agent, excipient, lubricant, binding agent, filler, operational approach routinely and process can be made for the medicine of tablet, pill, capsule or solid orally ingestible forms such as multiple corresponding slow releasing agent, controlled release agent; After the surfactants such as solubilizing agent, emulsifying agent, wetting agent, foaming or defoamer of routine, diluent, antiseptic, stabilizing agent, correctives, thickening agent etc. mix, by corresponding conventional method, can be made for oral drugs as liquid preparation forms such as water preparation, syrup; Cooperates with the solvent of the conventional appropriate format that uses in the injection and additives and operate, promptly can be prepared into the injection-type pharmaceutical preparation of the routines such as corresponding injectable powder, aqueous injection of confession intramuscular injection or used for intravenous injection.
The present invention also provides the purposes of water-soluble extract of red sage root in preparation angiotensin converting enzyme inhibitor class medicine, treatment hypertension, treatment hypertension companion heart failure, treatment hypertension companion diabetic nephropathy drugs.
The above-mentioned said salvianolic acid water extract that effective medicinal ingredient uses that can be used as of the present invention, its raw material is the natural drug Radix Salviae Miltiorrhizae, medicine source abundance, method is simple to extract preparation.Experimental result shows, with this extract at effective active composition as the angiotensin converting enzyme inhibitor medicine, can have the effect that suppresses Angiotensin-Converting more by force, not only can be used for hypertensive treatment, also can be used for the treatment of hypertension companion's heart failure and hypertension companion diabetic nephropathy, good effect, toxic and side effects is little.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
Description of drawings
Fig. 1 is salvianolic acid extract T of the present invention
1Measurement result to the Angiotensin-Converting activity influence.Wherein, the abscissa among the figure is represented Radix Salviae Miltiorrhizae extract T
1Concentration, vertical coordinate is represented ACE suppression ratio (%).
Fig. 2 is heterogeneity and the salvianolic acid extract T in the Radix Salviae Miltiorrhizae
1Measurement result to the Angiotensin-Converting activity influence.Wherein, the abscissa among the figure is represented Radix Salviae Miltiorrhizae heterogeneity and salvianolic acid extract T
1, vertical coordinate is represented ACE suppression ratio (%).
The specific embodiment
Embodiment 1 salvianolic acid extract T of the present invention
1Preparation
Get 1000 gram Radix Salviae Miltiorrhizaes, after crushed, use 25% alcohol dipping successively, each 24 hours, repeated impregnations 2 times (during dipping, mechanical agitation impregnation liquid 1 hour).Impregnation liquid is merged after-filtration, and ethanol is removed in distilling under reduced pressure, gets concentrated aqueous solution, and is with the deionized water dilution, centrifugal, standby.Get D-140 type non-polar macroporous resin dress post, with above-mentioned aqueous solution with the flow velocity of 20 ml/min by this macroporous resin column, wash post with 500 ml deionized water with the flow velocity of 20 ml/min then, reuse 75% ethanol elution, merge eluent, concentrating under reduced pressure, vacuum drying gets salvianolic acid extract T
1Dry powder 39.8 grams (yield about 4%).More than Zhi Bei salvianolic acid extract is brownish red solid matter, mildly bitter flavor.Adopt colorimetry, utilize phenolic compound and the potassium ferricyanide-ferric chloride to be chromogenic reaction, with danshensu product in contrast, measuring wherein contained Radix Salviae Miltiorrhizae total phenolic acids is 55% of gross weight.
Embodiment 2 salvianolic acid extracts suppress the Angiotensin-Converting activity test
1. the preparation of Angiotensin-Converting
Get lung tissue of rats,, clean, be cut into small pieces, break into homogenate with homogenizer with 10mmol/l glacial phosphoric acid potassium buffer.Homogenate was got 5000g centrifugal 10 minutes at 4 ℃, abandoned precipitation.Supernatant each 2 liters, changes liquid 4 times with dialysed overnight under the above-mentioned glacial phosphoric acid potassium buffer low temperature.Then in 4 ℃, 40, centrifugal 40 minutes of 000g abandons precipitation, supernatant is enzyme extract, packing, be stored in-20 ℃ standby.
2. salvianolic acid extract T
1Mensuration to the Angiotensin-Converting activity influence
Get 10ug/ml, 50ug/ml, the salvianolic acid extract T of 100ug/ml variable concentrations
110 μ l and zyme extract 10 μ l (containing total protein 10 μ g approximately), 37 ℃ were reacted 30 minutes, and establishing blank is 20 μ l buffer, and negative control is 10 μ l buffer and 10 μ l zyme extracts.After enzyme and medicine fully react, add fashionable property o-phthaldialdehyde, Hippuryl-histidyl-leucine (HHL) (phthalic aldehyde, hippuric acid-histidyl-leucine) (be mixed with 25mmol/L storage liquid with 25mmol/LNaOH, 1.25 * sodium borate buffer liquid 0.5mol/L contains NaCl 375mmol/L to reactant liquor 120 μ l, pH8.3, reactant liquor is that HHL storage liquid mixes with 1.25 * sodium borate buffer liquid at 1: 4), 37 ℃ were reacted 15 minutes, added 1N NaOH40 μ l cessation reaction.Add 20mg/mlo-phthaldialdehyde (phthalic aldehyde) (DMSO preparation) 10 μ l with the automatic sampler lucifuge, room temperature lucifuge reaction 10 minutes, automatic sampler adds 3N H hydrochloric acid 20 μ l cessation reactions, measure fluorescence intensity F with fluorescence detector in 30 minutes, excitation wavelength 405nm, emission wavelength 535nm calculates suppression ratio with following formula.As positive reference drug, its activity is respectively with the angiotensin converting enzyme inhibitor captopril of clinical use:
The results are shown in accompanying drawing 1.From Fig. 1 as seen, the present invention's salvianolic acid extract of the present invention T
1Activity with remarkable inhibition Angiotensin-Converting, its IC
50Be 8 μ g.
3. Radix Salviae Miltiorrhizae heterogeneity and salvianolic acid extract T
1Mensuration to the Angiotensin-Converting activity influence
For comparing red sage root water soluble ingredient, fat soluble ingredient of red sage root and salvianolic acid extract T
1To the active effect of Angiotensin-Converting, choose the main water soluble ingredient danshensu of Radix Salviae Miltiorrhizae, protocatechualdehyde respectively, the main liposoluble constituent Tanshinone I of Radix Salviae Miltiorrhizae, tanshinone (four kinds of Radix Salviae Miltiorrhizae monomer component standard substance are all available from the institute for drug control, Sichuan Province), and salvianolic acid extract T
1, it is 100ug/ml solution that above medicine all is mixed with concentration, experimentizes with reference to above-mentioned Angiotensin-Converting activity determination method, the results are shown in Figure 2.The result shows, salvianolic acid extract T
1The Angiotensin-Converting activity is had significant inhibitory effect, and suppression ratio is 97%; Red sage root water soluble ingredient danshensu and protocatechualdehyde have certain inhibitory action to the Angiotensin-Converting activity, and suppression ratio is respectively 64% and 50%; And fat soluble ingredient of red sage root Tanshinone I and tanshinone be to the active a few unrestraint effects of Angiotensin-Converting, and suppression ratio only is respectively 9% and 7%.
Embodiment 3 salvianolic acid extract T
1Influence to the renal hypertensive rat blood pressure
Modeling method: male and female SD rat, body weight 200-220 gram, Experimental Animal Center provides.Lumbar injection pentobarbital 30mg/kg anesthetized rat at rat left side waist skidding otch, goes out the left kidney tractive, separates the renal artery initial part, clamps renal artery with the 0.2mm silver brain clip, makes it narrow; And only to separate renal artery but without the narrow renal artery of silver brain clip (being the sham-operation rat) in contrast, skin suture.Per 2 weeks of postoperative are measured blood pressure once, blood pressure determination is measured the arteria caudalis systolic pressure with RBP-1B rat blood pressure meter (by China-Japan Friendship Hospital's development), when measuring at every turn, and triplicate, average as working as all blood pressures, postoperative 5 all systolic pressures＞18kPa persons are considered as Hypertensive Rats.
Experimental rat is divided into 4 groups: salvianolic acid extract T
1Group is (hereinafter to be referred as Radix Salviae Miltiorrhizae T
1Group, n=6), systolic pressure＞18kPa irritates stomach Radix Salviae Miltiorrhizae extract T every day
1(500mg/kg) continuous 4 weeks; Positive group (n=4), systolic pressure＞18kPa irritates continuous 4 weeks of stomach ramipril (1mg/kg) every day; Sham operated rats (n=4), systolic pressure＜14kPa is to irritate stomach, continuous 4 weeks with medicine equal-volume normal saline; Model group (n=6), systolic pressure＞18kPa, to irritate stomach with medicine equal-volume normal saline, continuous 4 weeks are respectively at 4 weeks after 2 weeks, the administration after the administration measuring the rat blood pressure value.The result is as shown in table 1.
Table 1 salvianolic acid extract T
1Influence to the renal hypertensive rat blood pressure
Annotate: #P＜0.05, compare with sham operated rats;
*P＜0.05 is with the preceding comparison of taking medicine;
*P＜0.01 is with the preceding comparison of taking medicine
By table 1 result as seen, blood pressure significant difference between model group and the sham operated rats, after experiment 2 weeks of beginning, the model group blood pressure rises to 20.06 ± 3.79kPa by 19.80 ± 4.50kPa, the former level of blood pressure stable maintenance and slightly raise (20.30 ± 4.09) after 4 weeks; Radix Salviae Miltiorrhizae T
1Group 2 week back blood pressures obviously descend, and drop to 15.89 ± 2.03kPa by 18.51 ± 1.77kPa, and the two has significant difference, drops to 14.15 ± 1.28kPa after 4 weeks, near the sham operated rats blood pressure level, with take medicine before relatively have extremely significant difference.Above result shows, salvianolic acid extract T
1The renal hypertensive rat animal blood pressure there is obvious reduction effect.
Embodiment 4 salvianolic acid extract T
1Influence to kidney type caused by hypertension left ventricular hypertrophy
Press the experimental implementation of embodiment 3, weigh (BW) after experiment finishes and cut open core dirty, clean bloodstain with normal saline, remove left and right atrium and right ventricle, weighing left ventricle weight in wet base (LVWW), calculate LVWW/BW ratio, estimate the influence of Radix Salviae Miltiorrhizae kidney type caused by hypertension left ventricular hypertrophy with this.The result is as shown in table 2.
Table 2 salvianolic acid extract T
1Influence to the left ventricular hypertrophy of kidney type caused by hypertension
Annotate:
*Compare with model group P＜0.01
The result as seen, renal vascular hypertension model group rat left ventricular hypertrophy, left ventricular mass and body weight ratio LVWW/BW are 2.55 ± 0.16, Radix Salviae Miltiorrhizae T
1Group rat left ventricular mass and body weight ratio LVWW/BW are the difference (P＜0.01) that has highly significant between 1.88 ± 0.20, two groups of ratios, show salvianolic acid extract T
1Can significantly alleviate the renal hypertensive rat left ventricular hypertrophy.
Claims (7)
1. salvianolic acid extract is characterized in that this extract is by following method preparation:
A, divide dipping to extract 1-2 time with the aquiferous ethanol of Radix Salviae Miltiorrhizae weight 5-20 10-40% doubly the salvia miltiorrhiza raw material pulverized, be at least 24 hours at every turn, obtain remaining water extraction solution after again dipping being extracted the solution filtration that obtains and separates the ethanol of removing wherein, concentrate, the dilution of reuse deionized water, centrifugal, standby;
B, the clear liquid reuse macroporous resin that obtains after a step process is adsorbed, then successively respectively water and aquiferous ethanol wash adsorbent resin respectively, merge eluent, remove the ethanol in the solution and concentrate, obtain extractum shape extract, dry dry powder; The aquiferous ethanol that eluent uses is the alcoholic solution of 70-75%.
2. extract as claimed in claim 1 is characterized in that what this extract was prepared by following method:
Get the 1000g Radix Salviae Miltiorrhizae, after crushed, use 25% alcohol dipping successively, each 24 hours, repeated impregnations 2 times; Impregnation liquid is merged after-filtration, and ethanol is removed in distilling under reduced pressure, gets concentrated aqueous solution, and is with the deionized water dilution, centrifugal, standby; Get D-140 type non-polar macroporous resin dress post, with above-mentioned aqueous solution with the flow velocity of 20 ml/min by this macroporous resin column, wash post with 500 ml deionized water with the flow velocity of 20 ml/min then, reuse 75% ethanol elution, merge eluent, concentrating under reduced pressure, vacuum drying gets the salvianolic acid extract.
3. the salvianolic acid preparation method of extract is characterized in that comprising the steps:
A, divide dipping to extract 1-2 time with the aquiferous ethanol of Radix Salviae Miltiorrhizae weight 5-20 10-40% doubly the salvia miltiorrhiza raw material pulverized, be at least 24 hours at every turn, obtain remaining water extraction solution after again dipping being extracted the solution filtration that obtains and separates the ethanol of removing wherein, concentrate, the dilution of reuse deionized water, centrifugal, standby;
B, the clear liquid reuse macroporous resin that obtains after a step process is adsorbed, then successively respectively water and aquiferous ethanol wash adsorbent resin respectively, merge eluent, remove the ethanol in the solution and concentrate, obtain extractum shape extract, dry dry powder; The aquiferous ethanol that eluent uses is the alcoholic solution of 70-75%.
4. method as claimed in claim 3 is characterized in that comprising the steps:
Get the 1000g Radix Salviae Miltiorrhizae, after crushed, use 25% alcohol dipping successively, each 24 hours, repeated impregnations 2 times; Impregnation liquid is merged after-filtration, and ethanol is removed in distilling under reduced pressure, gets concentrated aqueous solution, and is with the deionized water dilution, centrifugal, standby; Get D-140 type non-polar macroporous resin dress post, with above-mentioned aqueous solution with the flow velocity of 20 ml/min by this macroporous resin column, wash post with 500 ml deionized water with the flow velocity of 20 ml/min then, reuse 75% ethanol elution, merge eluent, concentrating under reduced pressure, vacuum drying gets the salvianolic acid extract.
5. the application of salvianolic acid extract as claimed in claim 1 or 2 in preparation treatment renal hypertension medicine.
6. the application of salvianolic acid extract as claimed in claim 1 or 2 in left ventricular hypertrophy medicine due to the preparation treatment renal hypertension.
7. the application of salvianolic acid extract as claimed in claim 1 or 2 in preparation angiotensin converting enzyme inhibitor medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100311717A CN102100742B (en) | 2003-03-27 | 2003-03-27 | Water-solubility extract of root of red-rooted salvia, preparation method thereof and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100311717A CN102100742B (en) | 2003-03-27 | 2003-03-27 | Water-solubility extract of root of red-rooted salvia, preparation method thereof and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117546 Division CN1534010B (en) | 2003-03-27 | 2003-03-27 | Water soluble extract of red sage root and its preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102100742A true CN102100742A (en) | 2011-06-22 |
| CN102100742B CN102100742B (en) | 2012-03-28 |
Family
ID=44153942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100311717A Expired - Lifetime CN102100742B (en) | 2003-03-27 | 2003-03-27 | Water-solubility extract of root of red-rooted salvia, preparation method thereof and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102100742B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106990054A (en) * | 2017-03-01 | 2017-07-28 | 浙江大学 | A kind of red rooted salvia quality determining method based on many target enzymes |
| CN110563677A (en) * | 2019-08-23 | 2019-12-13 | 惠州市九惠制药股份有限公司 | Salvianolic acid B and powder inhalation capsule thereof and preparation method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1129572C (en) * | 1998-09-11 | 2003-12-03 | 中国科学院上海药物研究所 | Preparation and application of tanshinpolyphenolic salt |
| CN1229324C (en) * | 2001-09-26 | 2005-11-30 | 中国医学科学院药物研究所 | Extraction process of tanshin general phenolic acid and its prepn and use |
-
2003
- 2003-03-27 CN CN2011100311717A patent/CN102100742B/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106990054A (en) * | 2017-03-01 | 2017-07-28 | 浙江大学 | A kind of red rooted salvia quality determining method based on many target enzymes |
| CN106990054B (en) * | 2017-03-01 | 2019-12-27 | 浙江大学 | Multi-target enzyme-based quality detection method for salvia miltiorrhiza medicinal material |
| CN110563677A (en) * | 2019-08-23 | 2019-12-13 | 惠州市九惠制药股份有限公司 | Salvianolic acid B and powder inhalation capsule thereof and preparation method |
| CN114848606A (en) * | 2019-08-23 | 2022-08-05 | 惠州市九惠制药股份有限公司 | Salvianolic acid B and powder inhalation capsule thereof and preparation method |
| CN114848606B (en) * | 2019-08-23 | 2023-10-31 | 惠州市九惠制药股份有限公司 | Salvianolic acid B and powder fog agent capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102100742B (en) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| FR2531864A1 (en) | ADMINICULUM FOR ANTI-TUMOR AGENTS COMPRISING AN EXTRACT FROM A RAW PHARMACEUTICAL PRODUCT INCLUDING ASTRAGALI RADIX | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| KR100529793B1 (en) | The extract of pine needle and the use thereof | |
| CN1534010B (en) | Water soluble extract of red sage root and its preparation method and use | |
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| RU2162704C2 (en) | Crataegus extract as preparation for prevention of sudden death as result of heart stop and cardiovascular damages induced by reperfusion | |
| KR100327894B1 (en) | Hypertension-treatment and colestearol-depressant composition comprising extract from mixture of panax notoginseng and salvia miltiorrhiza and method of preparing the same | |
| JP2007051129A (en) | Hypotensive agent | |
| JP2004075584A (en) | Therapeutic or prophylactic agent for vascular fibrosis | |
| CN102100742B (en) | Water-solubility extract of root of red-rooted salvia, preparation method thereof and application thereof | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN100417389C (en) | Medicine composition for treating microcirculation dysfunction and its preparing method | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| JP2001261569A (en) | Antiobestic agent | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig | |
| CN100531740C (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
| CN101843669A (en) | Chinese medicinal effective-part composition for treating coronary heart diseases | |
| CN100544747C (en) | A kind of treatment thoracic obstruction medicine and production method thereof | |
| CN101176772B (en) | Pharmaceutical composition made of cattail pollen and safflower | |
| CN1899393A (en) | Chinese medicine compound preparation for treating pulmonary heart disease and its preparation | |
| CN1593444A (en) | Prescription drug for treating cardiovascular and cerebrovascular diseases | |
| KR100213667B1 (en) | The composition showing antidiabetes | |
| CN1785283B (en) | Medicinal composition for treating cardiorascular disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20120328 |
|
| CX01 | Expiry of patent term |